S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM-BLAST PHASE (MPN-BP) INITIATING CELLS AND PROLONGS LEUKEMIA-FREE SURVIVAL (LFS) IN AN MPN-BP PDX MODEL

• Xiaoli Wang,
• Cing Siang Hu,
• Andrew Davis,
• Cecile Krejsa,
• Ronald Hoffman

Affiliations

Xiaoli Wang

1 Division of Hematology/Medical Oncology, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States

Cing Siang Hu

1 Division of Hematology/Medical Oncology, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States

Andrew Davis

1 Division of Hematology/Medical Oncology, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States

Cecile Krejsa

2 Kartos Therapeutics, Inc., Redwood City, United States

Ronald Hoffman

1 Division of Hematology/Medical Oncology, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, United States